GRAIL Faces Securities Fraud Lawsuit; Investors Urged to Participate

Investors who bought shares of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025, and February 19, 2026, are being given the opportunity to participate in a class action lawsuit alleging securities fraud. The Schall Law Firm, a national firm specializing in shareholder rights litigation, has initiated the process to inform affected investors.

The lawsuit claims that GRAIL issued misleading statements about its business prospects, particularly concerning the results and timeline of its NHS-Galleri trial, an initiative aimed at detecting late-stage cancers. The company is accused of concealing adverse facts related to the trial and presenting an overly optimistic outlook, despite evidence suggesting its three-year timeframe was insufficient to demonstrate the achievement of the study's primary endpoint. These alleged misrepresentations, according to the complaint, led to investor damages when the market learned the truth.

The Schall Law Firm, which represents investors globally in securities class actions, is urging investors who suffered losses during the specified period to contact them by August 4, 2026. The firm is offering free consultations to discuss shareholder rights and the details of the case. The class has not yet been certified, meaning participants are not yet represented by an attorney, and can remain absent class members if no action is taken.

The legal action is ongoing, and further details are expected to emerge as the case progresses through the court system. GRAIL has not yet issued a public statement regarding the lawsuit.